Cullinan Associates’s West Pharmaceutical WST Stock Holding History

Cullinan Associates’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30,000	Closed	-$9.83M	–	226
2024 Q4	$9.83M	Hold	30,000	–	–	0.63%	40
2024 Q3	$8.66M	Hold	30,000	–	–	0.49%	48
2024 Q2	$9.88M	Hold	30,000	–	–	0.56%	47
2024 Q1	$11.9M	Sell	30,000 -4,000	-12%	-$1.48M	0.67%	40
2023 Q4	$12M	Hold	34,000	–	–	0.67%	33
2023 Q3	$12.8M	Hold	34,000	–	–	0.74%	31
2023 Q2	$13M	Hold	34,000	–	–	0.71%	33
2023 Q1	$11.8M	Sell	34,000 -839	-2%	-$245K	0.69%	40
2022 Q4	$8.2M	Buy	34,839 +20,839	+149%	+$4.94M	0.45%	50
2022 Q3	$3.44M	Hold	14,000	–	–	0.22%	98
2022 Q2	$4.23M	Hold	14,000	–	–	0.26%	88
2022 Q1	$5.75M	Buy	+14,000	New	+$5.48M	0.3%	80

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DCP

Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Cullinan Associates's WST Position: Q1 2025 in Review

Cullinan Associates sold out of West Pharmaceutical (WST) in Q1 2025, closing a stake of 30,000 shares — an estimated $9.83M sold.

Cullinan Associates first reported a position in WST in Q1 2022 and held it in 12 quarters. The position peaked at $13M in Q2 2023. 715 funds tracked by Wall St. Rank hold WST as of Q1 2025.

Cullinan Associates reported no remaining West Pharmaceutical position as of Q1 2025 after selling out during the quarter.
Cullinan Associates sold 30,000 West Pharmaceutical shares in Q1 2025, an estimated $9.83M.
Cullinan Associates first reported a position in West Pharmaceutical in Q1 2022 and held it in 12 quarters.
Cullinan Associates's West Pharmaceutical position peaked at $13M in Q2 2023.
715 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2025.

Based on Cullinan Associates's 13F filing for Q1 2025, filed 22 Apr 2025.